Melanoma patients with metastases have a very low survival rate and limited treatment options. Therefore, the targeting of melanoma cells when they begin to invade and metastasize would be beneficial. An adhesion molecule that is upregulated at the vertical growth phase is the melanoma cell adhesion molecule (MCAM/MUC18). MUC18 is expressed in late primary and metastatic melanoma with little or no expression on normal melanocytes. We utilized the alphavirus-based DNA plasmid, SINCp, encoding murine MUC18 (SINCp c-muMUC18) for vaccination against B16F10 murine melanoma cells expressing murine MUC18. This vaccine effectively protected mice from lethal challenges with melanomaexpressing murine MUC18 in both primary and metastatic tumor models. Vaccination against MUC18 elicited effective humoral and CD8
Introduction
As it progresses through a multistep process, melanoma in humans switches from melanocytes to nevi, to radial growth phase (RGP) and subsequently to vertical growth phase (VGP) and the metastatic phenotype. These switches are associated with molecular and genetic changes. 1 Although patients with localized melanoma (stages I and II) have a good prognosis, the 5-year survival rate for patients with stage IV is less than 11%. 2 Metastatic melanoma patients have limited treatment options. Therefore, the targeting of melanoma cells when they begin to invade and metastasize would be beneficial. This suggests that there is a great need for therapy for patients whose tumors have advanced from the RGP to the VGP. A specific adhesion molecule known as melanoma cell adhesion molecule (MCAM/MUC18) is upregulated at the VGP and plays an important role in melanoma progression. 3, 4 MUC18 is a membrane glycoprotein that contains five immunoglobulin (Ig) superfamily-related extracellular domains, a transmembrane region and a short cytoplasmic region. [5] [6] [7] MUC18 is expressed on advanced and metastatic melanoma cells but not on normal melanocytes. 8 We recently investigated the use of fully humanized antibodies for blocking MUC18. Treatment with anti-MUC18 antibodies slowed tumor growth and reduced the number of experimental metastases in nude mice when challenged with human melanoma cells or osteosarcoma cells expressing MUC18. 9, 10 DNA vaccines have a number of advantages when compared to other vaccines. They are very stable, easily produced, inexpensive and safe. One of the most attractive features is the ability of DNA vaccines to induce both humoral and cell-mediated responses. 11 Although there is significant potential for DNA-based vaccines, current formulations have had low potency in clinical trials. 12 The development of alphavirus-based DNA vaccines is a new design of DNA plasmid that shows promise in which the target antigen is expressed under the control of an alphaviral replicase. Mouse studies have shown that far less DNA is needed for therapeutic efficacy with alphavirus-based DNA plasmids compared with conventional DNA plasmids. 13, 14 Alphavirus-based DNA vaccines have the ability to overcome the inefficiencies of conventional plasmids by stimulating the innate immune response through activation of the ribonuclease L and double-stranded RNA-dependent protein kinase pathways during replication of the viral genome. 15 The activation of these pathways leads to the death of the transfected cell, which has been shown to enhance vaccine immunogenicity. 16 The advantage of the alphavirus plasmid over a conventional plasmid may potentially lead to an important therapy for the treatment of cancer.
Increasing the amount of protein expressed by a DNA vaccine may enhance the immunological response to the gene of interest within the vaccine. [17] [18] [19] [20] The vector used in this study is an alphavirus-based DNA plasmid. However, when the alphavirus non-structural proteins start to replicate its genome, host cell protein synthesis is inhibited. 21 Alphaviruses have developed a way around this to maximize its protein expression. The first 226 nucleotides (nt) of the Sindbis virus capsid gene are responsible for increased protein expression of the structural proteins. 22 The use of the first 226 nt of the capsid sequence may be used to create a more potent vaccine, because the protein levels of the antigen fused together with this sequence can increase the antigen expression more than 10-fold. 22 Unlike other vaccine regimens that were directed against melanoma antigens such as gp-100 and Mart-1 (also expressed on normal melanocytes), our vaccine is targeted against MUC18 (not expressed on normal melanocytes). In this study, we report on the treatment of melanoma using an alphaviral-based DNA vaccine expressing the novel antigen, MUC18. Our vaccine elicited effective humoral and CD8
+ T-cell immune responses, which resulted in antitumor responses against melanoma-expressing MUC18.
Results
Vaccination against murine MUC18 protects mice against B16F10 cells overexpressing MUC18 in primary and metastatic tumor models
To determine the efficacy of vaccination against MUC18, we constructed the DNA-based alphavirus plasmid, SINCp, coding for murine MUC18 (SINCp muMUC18). Murine MUC18 was also cloned into SINCp with the first 226 nt of the Sindbis virus capsid gene in front of it (SINCp c-muMUC18) (Figure 1a ). Protein expression of murine MUC18 was demonstrated by Western blot analysis of BHK transiently transfected cells (Figure 1b) . The expression of murine MUC18 was greater when the first 226 nt of the capsid gene were cloned in front of MUC18 than without the capsid gene (Figure 1b, lane 3) . As the expression of murine MUC18 from the SINCp muMUC18 plasmid was extremely low (Figure 1b , lane 2), we decided to use only the SINCp c-muMUC18 plasmid in the vaccination models.
We initially vaccinated C57BL/6 mice with SINCp c-muMUC18 and challenged them with parental B16F10 cells. SINCp c-muMUC18 had no effect on tumor incidence or survival in this model (data not shown), probably owing to the extremely low expression of murine MUC18 in this cell line (Figure 1c) . The low expression of MUC18 in B16F10 cells is not representative of MUC18 expression in human metastatic melanoma. 4, 23 To mimic the levels of MUC18 expression on human metastastic melanoma cells, we developed a B16F10 cell line overexpressing murine MUC18 for tumor challenge. As B16F10 cells express very low levels of murine MUC18 (Figure 1c , lane 1), we wanted to increase its expression so that murine MUC18 was at comparable levels as in advanced human disease. 4, 23 Therefore, B16F10 cells were transduced with a retrovirus encoding the gene for murine MUC18 and expression of murine MUC18 protein levels was verified by Western blot analysis (Figure 1c) . We isolated two clones that overexpress MUC18 (cl7 and cl13) ( Figure 1c , lanes 2 and 3, respectively). Clone B16F10 murine MUC18 cl7 ( Figure 1c , lanes 2) was used for challenge in the vaccination studies and will be referred to as MUcl7.
The development of an effective antitumor response by vaccination against a self-antigen is necessary for Although immunization with SINCp c-muMUC18 could protect against MUcl7 challenge, this method was ineffective against established MUcl7 tumors (data not shown). This could be due to the aggressive nature of these cells to outgrow the effect of the vaccination. Vaccination against MUC18 for the treatment of melanoma MC Leslie et al low levels of murine MUC18), but a strong absorbance when incubated with MUcl7 cells (Figure 3a) . Also antibody responses showed a strong absorbance against MUcl7 cells when incubated with serum from SINCp c-muMUC18 but not with serum from mice immunized with SINCp b-gal (Figure 3a) . To determine whether a Th1 response was initiated upon vaccination against MUC18, we analyzed the development of IgG2a antibodies. Interferon (IFN)-g expression is a hallmark of the Th1 response, which leads to an isotype switch to IgG2a. In our studies, IgG2a antibodies were detected using serum from mice vaccinated with SINCp c-muMUC18, but not with serum from mice immunized with SINCp b-gal (Figure 3c ), suggesting that the vaccination induced a Th1 response. Collectively, these results indicate that vaccination with murine MUC18 generated specific antibodies against the respective antigen.
DNA vaccination against murine MUC18 induces T-cell-mediated lysis
In the last set of experiments, we analyzed the cytotoxic T-lymphocyte (CTL) response as a potential mechanism for tumor rejection. The results depicted in Figure 4 show that SINCp c-muMUC18 generated antigen-specific CTLs against murine MUC18 using a DNA Fragmentation enzyme-linked immunosorbent assay (ELISA) with splenocytes from C57BL/6 mice that were immunized six times weekly with SINCp c-muMUC18 or SINCp b-gal. At all effector-to-target ratios, splenocytes from SINCp c-muMUC18-vaccinated mice had significantly higher CTL activity when compared to splenocytes from SINCp b-gal-vaccinated mice (P ¼ 0.0286).
Discussion
We showed for the first time that DNA-based vaccination against the novel melanoma antigen MUC18/MCAM protected mice from lethal challenges of melanoma cells. We developed vaccination against murine MUC18 in a syngeneic model, which is representative of tumor vaccination therapy in a clinical setting.
Immune recognition of melanoma cells by B-and T-lymphocyte has been studied extensively and a number of melanoma antigens have been identified. 24, 25 Melanoma antigens generally belong to three categories: (a) differentiation antigens, (b) cancer/testis antigens and (c) overexpressed proteins and mutations responsible for the malignant phenotype. The latter group, which includes the antigen used in this study, may be the Vaccination against MUC18 for the treatment of melanoma MC Leslie et al most attractive for cancer vaccines, as they would lead to less antigen-loss escape variants by targeting proteins that were vital to malignancy. We developed a vaccination strategy against the novel melanoma antigen, MUC18, which is not expressed on normal melanocytes, but its expression increases with the progression of melanoma. 8 We chose to use an alphavirus-based DNA plasmid instead of a conventional plasmid for vaccination because several studies have shown them to be superior through their ability to activate innate immunity. [13] [14] [15] Vaccination against MUC18 was effective in preventative models for murine MUC18. It was clearly demonstrated that SINCp c-muMUC18 induced antitumor immune responses in preventative mouse melanoma models of both primary tumors as well as experimental lung metastases. The tumor incidence as well as the number of lung colonies was greatly reduced in mice vaccinated with SINCp c-muMUC18 compared to mice vaccinated with the SINCp b-gal. However, immunization with SINCp c-muMUC18 had no antitumor effects against parental B16F10 cells, probably owing to the extremely low expression of murine MUC18 in those cells.
In contrast to total protection provided by immunization with foreign model tumor-associated antigens such as b-gal or ovalbumin, 14,26-28 protection against tumor challenge was not completely observed in all of the mice vaccinated with SINCp c-muMUC18. These differences suggest that stronger immune responses are elicited with the use of foreign tumor antigens as compared to selfantigens. Several strategies to increase the efficacy of vaccination are in the process of evaluation such as the co-expression of specific cytokines, co-expression of accessory molecules, modification of intra-and extracellular trafficking, increasing the efficacy of transfection, increasing the amount of antigen produced and maximizing the ability of antigen to be presented by dendritic cells. 12 These strategies used with an alphaviral vector may enhance the effectiveness of vaccination against murine MUC18.
The potential also exists for vaccination using a primeboost protocol to enhance the immmunogenicity against MUC18. Heterologous prime-boost vaccines either with a DNA plasmid for the prime and a viral vector for the boost or two different viral vectors expressing the same antigen have shown promising results for the therapy of cancer. [29] [30] [31] The use of antibodies against MUC18 has been effective therapy for reducing tumor growth and metastases in animal models. 9, 10 Although vaccination against murine MUC18 produced specific antibodies, the antibody responses generated by vaccination with SINCp c-muMUC18 took at least five vaccinations to form antibodies against murine MUC18 (data not shown). The delay in antibody development suggests that stronger immunogenicity exists when using foreign antigens in mice as compared to self-antigens.
For cancer immunotherapy, the cell-mediated response from vaccination should induce a Th1-type response including a strong CTL response. 32, 33 An isotype switch to IgG2a is indicative of a Th1 response because IFN-g expression leads to this switch. IgG2a antibody responses from immunization with SINCp c-muMUC18 were generated in our study. The development of these antibodies suggests that a Th1 response was initiated by the vaccine. In vitro cytotoxicity using splenocytes from SINCp c-muMUC18-vaccinated mice had a higher activity than mice immunized with SINCp b-gal against tumor cell targets expressing murine MUC18. Also, the depletion of CD8 + T cells reduced any antitumor effects produced by vaccination showing the importance of these cells for MUcl7 destruction. Although the depletion of CD4 + T cells had no direct antitumor effect, this does not diminish the importance of these cells in developing antitumor responses. CD4 + T cells may have played an indirect role in the antitumor response through the induction of antibodies and antitumor CD8 + T-cell responses after vaccination. The development of IgG2a antibodies along with cytotoxic splenocytes and CD8 + T-cell depletion provide evidence that a cell-mediated response was developed from vaccination using SINCp c-muMUC18.
B16F10 is a very fast growing mouse melanoma with mice succumbing to death around 21-28 days. Accordingly, therapeutic vaccination was not effective in our model of vaccination against murine MUC18, probably owing to the length of time before the development of an immune response. Five weekly vaccinations were needed before mice had a detectable antibody response against murine MUC18. Although our study was not effective in therapeutic models, some studies that develop rapid antitumor responses have shown to be effective against established B16 tumors. 34 The use of future vaccine strategies against MUC18 may lead to a more rapid induction of immune responses with the ability to overcome established tumors. There may be a potential for autoimmunity when vaccinating against murine MUC18 in mice. After vaccination, there were no observable negative reactions to mice that were vaccinated against murine MUC18. Mice gained weight normally and were in good health for well over a year. Upon killing and dissection, there were no abnormalities present.
Although there were no visible autoimmune effects seen in mice vaccinated with SINCp c-muMUC18, there is potential for autoimmunity against cells expressing MUC18 in humans. The identification of tissues expressing murine MUC18 in mice has not been determined, so we do not know if the pattern of expression in mice is representative of expression of human MUC18 in humans. As human MUC18 is expressed in endothelium, smooth muscle and peripheral nerve tissue, 35 there is potential for destruction of those tissues when vaccinating against human MUC18. However, MUC18 is highly overexpressed on human metastatic melanoma cells. We are optimistic that the immunity that develops in vaccinated patients will be directed against the rapidly dividing melanoma cells that develop overexpression of human MUC18 compared to the normal cells that express much lower levels of the same antigen. Most patients diagnosed with early-stage melanoma have complete surgical excision of their primary tumor and involved lymph nodes. However, patients with thick primary lesions or positive lymph nodes have a significant chance of recurrence, and immunization against a protein that is essential for melanoma invasion and metastasis may have significant promise to help prevent recurrence. This study highlights the potential of targeting proteins essential for the malignant phenotype 
Materials and methods

Cell lines
The highly metastatic B16F10 mouse melanoma cell line was generated by IJ Fidler and obtained from Dr Honnavara Ananthaswamy (MDACC). We created the MUcl7 cell line from B16F10 by retroviral transduction with murine MUC18. pLNCX2 (Clontech, Mountain View, CA, USA) is a retroviral expression plasmid that was used for stable transfection of murine MUC18 into B16F10. pLNCX2-muMUC18 was created by inserting murine MUC18 into it by restriction digestion and was transfected into the AmphoPack-293 Packaging Cell Line (Clonetech) using LipoGen transfection reagent (InvivoGen, San Diego, CA, USA). Twelve hours after transfection, media were removed and replaced with fresh Dulbecco's modified Eagle's medium. Forty-eight hours later, the virus containing media was collected and filtered through a 0.45 mm low protein-binding filter (Whatman, Clifton, NJ, USA). The filtered virus containing media was then added to a six-well plate of 30% confluent B16F10 cells. Polybrene was added to a final concentration of 6 mg/ml. Twenty-four hours later, the virus containing media was removed and fresh media was added to the infected B16F10 cells. In vivo depletion of CD8 + and CD4 + T cells
Hybridoma clones GK1.4 (rat anti-mouse CD4) and 2.43 (rat anti-mouse CD8) were purchased from ATCC (Manassas, VA, USA). Hybridoma culture supernatants were purified using a GammaBind Plus Sepharose (Amersham Biosciences, Piscataway, NJ, USA) column. Control rat IgG was purchased from Sigma-Aldrich (St Louis, MO, USA). Four days after the last vaccination, mice were injected intraperitoneally with 100 mg of GK1.4 (anti-CD4) or 2.43 (anti-CD8) antibody. Antibody injections were performed at days À3, À1, 0, 3, 7, 14 and 21 with tumor challenge at day 0. Efficacy of depletion was greater than 95% as determined by flow cytometry and remained throughout the duration of the experiment.
Flow cytometry
Target cells were incubated for 1 h at 41C with either immune serum or control serum diluted in PBS containing 10% fetal bovine serum (FBS) (PBSF10). Cells were washed three times in PBS and then fluorescein isothiocyanate-labeled goat anti-mouse IgG+IgM, IgG or IgG2a diluted 1:250 in PBSF10 was added to the cells and incubation was continued for 30 min at 41C. The cells were washed three times in PBS and were analyzed by flow cytometry using an EPICS Profile Analyzer (Beckman Coulter Inc., Fullerton, CA, USA).
In vitro CTL induction and activity
Female C57BL/6 mice were injected i.m. with SINCp c-muMUC18 or SINCp b-gal six times as described above. A week after the sixth DNA vaccination, spleens were harvested and total splenocytes were activated by co-incubation with MUcl7 cells (40:1) pretreated with 25 mg/ml mitomycin C for 25 min. Cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 25 mM L-glutamate, penicillin (100 U/ml), streptomycin (100 mg/ml) (Gibco BRL, Rockville, MD, USA), 50 mM 2-mercaptoethanol and 10% FBS. Murine IL-2 (30 U/ml) (PeproTech Inc., Rocky Hill, NJ, USA) was added to the culture on day 0. After 5 days of incubation at 371C with 5% CO 2 , non-adherent cells were harvested and plated with target cells at different effector-to-target ratios. The cytolytic activity of the /ml) were incubated with 10 mM 5-bromodeoxyuridine (BrdU) for 24 h at 371C in 5% CO 2 before two washes with RPMI complete medium. The cultured splenocytes were serially diluted in triplicate wells of 96-well round-bottom plates. MUcl7 cells (1 Â 10 5 /well) were co-incubated with serially diluted splenocytes in quadruplicate wells of 96-well round-bottom plates with a final volume of 200 ml RPMI complete medium per well. The plates were incubated at 371C for 5 h with 5% CO 2 . Labeled DNA fragments were separated from labeled intact genomic DNA by centrifugation (10 min at 250 g). Soluble DNA fragments present in the supernatant were quantified using the cellular DNA Fragmentation ELISA. Anti-DNA antibody was adsorbed in the wells of a flat-bottom microtiter plate. One hundred microliters of the supernatants containing BrdU-labeled DNA fragments from each sample were added to the microtiter plate and allowed to bind the immobilized anti-DNA antibody overnight at 41C. After three washes, the immunocomplexed BrdUlabeled DNA fragments were denatured and fixed to the surface of the microtiter plate by microwave irradiation. Labeled fragments were detected using anti-BrdU antibody conjugated to horseradish peroxidase. The amount of peroxidase bound to the immune complex was determined by the addition of a 3 0 ,3 0 ,5 0 ,5 0 -tetramethyl benzidine substrate. Color development progressed for 5 min and the reaction was terminated by the addition of 1 M H 2 SO 4 . Absorbance of the colorimetric product was measured at 450 nm. As a 100% lysis reference control, the MUcl7 cell (1 Â 10 5 /well) genomic DNA was denatured by NaOH treatment and reacted with anti-BrdU antibody. MUcl7 cells cultured without splenocytes served as a negative control.
Statistical analysis
Log-rank test for survival curves and Mann-Whitney non-parametric tests for metastases and effector/target lysis models were performed using Prism 4.0 Graphpad Software.
